Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Molecular Biological Determinations of Meningioma Progression and Recurrence

  • Stefan Linsler,

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

  • Dennis Kraemer,

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

  • Christina Driess,

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

  • Joachim Oertel,

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

  • Kai Kammers,

    Affiliations Department of Statistics, TU Dortmund University, Dortmund, Germany, Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

  • Jörg Rahnenführer,

    Affiliation Department of Statistics, TU Dortmund University, Dortmund, Germany

  • Ralf Ketter ,

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

  • Steffi Urbschat

    Affiliation Department of Neurosurgery, Saarland University, Homburg/Saar, Germany

Molecular Biological Determinations of Meningioma Progression and Recurrence

  • Stefan Linsler, 
  • Dennis Kraemer, 
  • Christina Driess, 
  • Joachim Oertel, 
  • Kai Kammers, 
  • Jörg Rahnenführer, 
  • Ralf Ketter, 
  • Steffi Urbschat


Meningiomas are tumors that arise from the coverings of the brain or spinal cord. 5% of the cases turn into malignant forms with aggressive clinical behavior and increased risk of tumor recurrence. One hundred and five patients with meningiomas were operated by open surgery. To investigate predictors of meningioma recurrence in total 124 samples of 105 patients were investigated by iFISH. Dual-probe hybridization was performed to access chromosomal alterations of chromosomes 1p-, 9p- and 22q. Additionally, methylation of TIMP3 and p16 was analyzed with MS-PCR. Of the 105 investigated tumors 59.1% (62/105) were WHO grade I, 33.3% (35/105) were WHO grade II and 7.7% (8/105) were anaplastic meningiomas (grade III), respectively. The histopathological data correlates with the recurrence rate of the investigated meningiomas. Hypermethylation of TIMP3 was detected in 13.3% of all meningiomas: 10.9% in WHO grade I meningiomas, 25.0% in grade II and 14.3% in grade III meningiomas, respectively. No correlation of TIMP3 hypermethylation with tumor recurrence or WHO grade (p = 0.2) was observed. Interestingly, deletion of 1p36 emerged as a significant predictor of shorter overall survival (log rank test, p<0.001), whereas TIMP3 promoter methylation had no significant effect on overall survival (log rank test, p = 0.799). The results of the current study support the finding that the deletion of chromosome 1p is an independent marker of meningioma recurrence and progression (p = 0.0097). Therefore the measurement of genetic aberrations in meningiomas allows in a combined histological approach a more precise assessment of the prognosis of meningiomas than histopathology alone.


Meningioma is a tumor composed of neoplastic meningothelial cells and accounts for 13 to 26 percent of intracranial tumors. In its sporadic form, it is typically benign and slow growing, appearing mostly in the later decades of life. Histological features allows for the division of meningiomas into three grades: benign meningiomas (WHO grade I), atypical meningiomas (WHO grade II) which represent 4.7 to 7.2 percent of all meningiomaş and anaplastic meningiomas (WHO grade III) representing 1.0 to 2.8 percent of all meningiomas. However, more than eight percent of all meningiomas are characterized by aggressive clinical behavior with increased risk of tumor recurrence [1][5].

Conventional cytogenetic analysis of meningiomas often reveals the frequent entire or partial losses of chromosome 22. Extensive studies by loss of heterozygosity (LOH) also have shown frequent allelic losses on the long arm of this chromosome, pinpointing the tumor suppressor locus in the vicinity of the NF-2 gene [6]. This is supported by the fact that patients with type II neurofibromatosis, who have constitutional mutations of the NF2 gene on the long arm of chromosome 22 (22q12.2), often present with multiple meningiomas. However this hereditary alteration has little or no influence on progression [7], [8]. A second tumor suppressor gene on chromosome 22 on 22q12.3 is the gene for the tissue inhibitor of metalloproteinase 3 (TIMP3), which appears to be involved in meningioma progression and a high-grade meningioma phenotype [9], [10]. TIMP3 hypermethylation seems to be associated with the allelic loss of 22q12. Moreover, hypermethylation of the TIMP3 promoter has been identified as a common reason of decreased TIMP3 expression levels in numerous tumors like secondary glioblastomas, kidney cancer, or pancreatic adenocarcinomas [11], [12], [13], [14], [15]. As to intracranial tumors, methylation of MGMT in gliomas [16] and of TIMP3 [9] and p16 [17], [18] in meningiomas seems to be associated with aggressive tumor behavior.

The p16 pathway, which has been found to be altered in more than 80% of human cancers [17], [34], [35], is located on 9p12, one of the investigated chromosomal regions investigated in this present study by FISH [36]. It has recently been proven that hypermethylation of a normally unmethylated CpG island in the promoter region of p16 correlates with its loss of transcription in various primary cancers [15], [36][39]. Other studies of the p16 gene have found homozygous deletions, mutations or transcriptional inhibition by methylation in a large number of different human tumor types [40][42].

In contrast to other solid tumors, progression of meningiomas is correlated with increasing hypodiploidy, showing characteristic clonal evolutions that mostly include chromosomes 14,18, and 19 and, more rarely, 6 and 10. Structural aberrations are rare, except for the loss of the short arm of one chromosome 1, which appears to be the decisive step for anaplastic growth [3], [4], [19][27].

In 2001, Zang reported a genetic model of tumor progression in meningiomas [8]. It was shown that the loss of chromosome 22 and the deletion of one short arm of one chromosome 1 was followed by complete or partial loss of additional chromosomes, in particular of chromosomes 6, 10, 14, 18, 19 [3], [8], [21], [24], [28][33]. Based on these findings, we applied a new mathematical model for tumor genesis to a group of 661 cytogenetically characterized meningioma patients, including 53 patients with tumor recurrences [3]. This model allows for estimating the probability of recurrences in meningiomas based on their genetic aberrations. The findings prompted us to investigate the loss of the short arm of one chromosome 1 in meningiomas in daily clinical practice.

Since the publication of Ishino and coworkers in 1998 the fluorescence in situ hybridization (FISH) technique has provided new insights into interphase cytogenetics and is applicable now to clinical practice. Therefore the time-consuming cell culture for conventional chromosome analysis is not further necessary. Instead of paraffin embedded tumor samples, also fresh tumor samples that are speckled on microscope slides can be used.

In the current study we examined 124 meningioma samples out of 105 prospective meningioma patients for the partial loss on chromosomes 1p, 9p and 22q, using double-target iFISH. The first aim of this study was to analyze if the iFISH results predict malignant behavior and recurrence of meningiomas as well as conventional cytogenetic analysis. The second aim of this study was to examine the promoter hypermethylation of TIMP3 and p16 in meningiomas in order to evaluate the impact of these markers for the biological behaviour of meningiomas.

Materials and Methods

Patient population

We performed a prospective study on 124 tumor samples from 105 meningioma patients [76 women and 29 men] operated at the Department of Neurosurgery, Saarland University, between January 1997 and December 2010. The average age of the overall patient population at the date of first surgery was 57.2 years [SD  = 13.3 years], for female patients 58.1 years [SD  = 12.0 years], and for male patients 54.8 years [SD  = 16.3 years]. Written informed consent was obtained from each patient participating in the study.

Follow up

Patients were examined in the neurosurgical outpatient department of the Saarland University, either within routine follow-up or upon appearance of neurological symptoms. A recurrence was defined as new evidence of tumor in CT or NMR after previous complete extirpation (Simpson grades 1 and 2) [43]. The Simpson grade 2 was established on the basis of the operation report and the postoperative CT or NMR investigation.

Tumor extirpation

Complete surgical extirpation of the tumor was defined as Simpson grades I and II. This corresponds to a macroscopically complete tumor resection with bipolar coagulation of the dura insertion.

Tumor histology

Meningioma grade was assessed by a combined histologic [21], [22], [32], [44][46] and morphometric approach on routinely HE and Ki-67/Feulgen stained formalin-fixed, paraffin-embedded tissue sections [21]. The 105 meningiomas comprised 63 tumors of WHO grade I, 35 tumors of WHO grade II, and 7 tumors of WHO grade III.

All tumors were classified according to the WHO classification of tumors of the nervous system of 2007 [46].

In total 124 different probes were investigated from the 105 patients. In 91 tumors (86.6%), only one surgical procedure was performed, in 10 patients (9.5%) 2 surgery procedures, in 3 patients (2.9%) 3 operations due to recurrence, and in 1 patient 4 surgical approaches was necessary.

Table 1 and 2 contains a breakdown of age, sex, WHO grade, chromosomal aberrations, and methylation status of TIMP3.

Table 1. Correlation between clinical variables and WHO tumor grade in meningiomas.

FISH analysis

Tissue specimens from tumors were obtained freshly after surgery and dapped on clean microscope slides previously silanized. After Delauney fixation for 30 sec, slides were stored at −20°C until further FISH analysis. The slides were treated with RNAse for thirty minutes at 37°C and placed three times in 2xSSC for five minutes at RT. Cells were digested in 100 ml 0,01 M HCL with 10 mg pepsin (Serva Heidelberg, Germany) for 1 min and 45 sec at 37°C. Slides were dipped in 1xPBS for 5 min, 4%PFA/1xPBS for 10 min for fixation and 1xPBS for 5 min. They were then dehydrated in 70%, 80%, 95% ethanol and air dried. Dual-probe hybridization was performed using locus-specific probes for 1p36, 22q11 and 9p21 (Abbott, Germany and Metasystems, Germany). Target and probe were separately denatured for 5 minutes at 73°C. Target slides were dehydrated in 70%, 80%, 95% ethanol. Then probes were pipette on slides and incubated overnight at 37°C in a humidified chamber. Stringency wash was performed in 0.4xSSC/0.3%SDS for 2 minutes at 73°C and 2xSSC/0.1% SDS at RT. Finally, slides were counterstained with DAPI antifade (Vectashield, Vector Laboratories).

At least 200 non-overlapping nuclei per sample were counted for evaluation according to Hopman-criteria [47], using an Olympus AX70 fluorescence microscope. Figures 1a and 1b illustrate the mapping of FISH probes.

Figure 1.

Figure 1a: Two color FISH for chromosome 1p36/22q11 (Metasystems). Figure 1b: Probe map for dualcolor probe 1p36/9p21 and 22q11 (Metasystems).

Cut-offs for alterations was determined by comparison with normal human lymphocytes control samples at 10% for deletions of 1p36, 22q11 and 9p21.

DNA extraction

Extraction of genomic DNA from snap frozen tumor tissue was performed with standard methods with samples more than 0.3 g and QIA DNA Mini Kit for samples with less than 0.3 g (QIAGEN, Hilden). DNA-Isolation from peripheral blood leukocytes was performed according to standard protocols [48].

Methylation analysis with MS- PCR and sequencing

Sodium bisulfite treatment of 500 ng DNA was performed with the EZ Methylation Gold™ Kit (Zymo Research Corporation) according to the manufacturer's protocol. PCR analyses were performed with 70 to 80 ng of the bisulfite-modified DNA as template using 0.2 μl (5 U/μl) of HotStar Taq DNA Polymerase (QIAGEN, Hilden) in 1× Qiagen PCR-buffer with 0.25 mmol/l of each dNTP and 0.1 μmol/l of each primer. The primers used in this study are described in the literature by Herman et al. [49] (p16) and Righini et al. (TIMP3) [50]. We used 0.5 μl MgCl2 (25 mM) (Quiagen) and 1.25 μl DMSO (5%v/v) for MS-PCR of TIMP3 as PCR-additive. MS-PCR with p16-primers was carried out for 37 (unmethylated specific analysis)/40 cycles (methylated specific analysis); 40 cycles TIMP3-MS-PCR with specific primers for both methylated and unmethylated alleles. MS-PCR was carried under the following conditions: 15 min initial denaturation at 95°C followed by 40 cycles of 1 min denaturation at 95°C, 1 min primer-annealing at 65°C (p16)/59°C (TIMP3), 1 min extension at 72°C and a final extension of 1 min at 72°C. As a negative control we added water in place of DNA and as a positive control we used Universal Methylated Human DNA (Zymo Research). PCR-products were separated on 2–3% agarose gels, than stained with ethidium bromide. Bands were visualized under UV (UV-transilluminator Wealtec, Sparks, USA), recorded (camera CU105M, 8030102 Rainbow, Japan) and detected (DeVision G, Vers. 2.0; Devon Science Tec GmbH, Hohengangern, Germany). Exemplary products of gelelectrophoresis are shown in Figure 2.

Figure 2. Demonstration of PCR products of TIMP3 in gelelectrophoresis: MN 123 and MN 60 =  patients with positive methylation status of TIMP3.

MN 2 =  patient without methylation.

Also, we analysed methylation status of p16 and TIMP3 by sequencing the regions of CpG-Islands as described in previous studies [17], [51]. The PCR products were extracted and subjected to cycle sequencing with BigDye Terminator sequencing kit and analysed on an ABI 3730 automated DNA capillary sequencer (Genterprise, Mainz, Germany).


Comparison of survival times between groups defined by methylation status was performed by Kaplan-Meier curves and with two-sided log rank tests. Univariate and multivariate Cox regression analysis was performed to identify significant predictors for survival and tumor recurrence. Stepwise backward selection based on the AIC (Akaike Information Criterion) was used for variable selection for the multivariate Cox model. Effects in all models were quantified by hazard ratio estimates with corresponding 95% confidence intervals.

All p-values were calculated with two-sided tests. Median progression free survival rates were calculated using the Kaplan-Meier method.

Ethics Statement

We obtained ethical approvel from local ethics committee for “The role of high risk of local recurrence in meningioma as indicated by the genetic progression score” (ethical approval No. 178/07) involving both, Department of Human Genetics, Saarland University and Neurosurgical Clinic, Saarland, University Medical School.

Written informed consent was obtained from each patient participating in the study.


We performed a prospective study on 124 tumor samples from 105 meningioma patients. The sex ratio was 2.6:1 in favor of females (76 women and 29 men). The average age of all patients at the date of first surgery was 57.2 years, and females were slightly but non-significant older on average (58.1 years vs. 54.8 years), see Table 1 and Table 2.

In 91 tumors (86.6%), only one surgical procedure was performed, in 10 patients (9.5%) 2, in 3 patients (2.9%) 3, and one patient had 4 times a tumor resection.

The histological results showed in 62 cases (59.05%) a WHO grade I tumor, in 35 cases (33.33%) a WHO grade II and in 8 cases (7.62%) a WHO grade III. The WHO grade was significantly correlated with tumor recurrence (p = 0.0026; Table 1; Figure 3).

Figure 3. Kaplan-Meier survival curves for times to recurrence of meningioma patients; patients are split into 3 subgroups according to WHO grades.

In 59% of the investigated cases we detected chromosomal aberrations by FISH analysis: loss of the long arm of chromosome 22 in 48.6% (51/105), loss of the chromosomal region 1p36 in 35.2% (37/105) and loss of the chromosomal region 9p21 in 6.67% (7/105).

Breaking down the FISH results to the respective WHO grading: monosomy 22 was detected in 45.2% (28/62) of WHO grade I, 48.6% (17/35) in grade II and 75% (6/8) in grade III meningiomas. Univariate as well as multivariate Cox regression analysis revealed no correlation with tumor recurrence (p = 0.771; p = 0.2, Table 3).

In WHO grade I meningiomas loss of 1p36 was detectable in 27.42% (17/62), in grade II in 27.1% (13/35) and in anaplastic meningiomas in 87.5% (7/8) of cases. Table 2 shows the number of recurrences and Figure 4 the time to recurrence, stratified by deletion of the short arm of one chromosome 1 (deletion of 1p36). Recurrences after complete tumor extirpation were observed in 21 of the 105 cases (20%). The deletion of 1p36, was found to be highly statistically significant predictive for the recurrence of a given meningioma in univariate Cox-regression analysis (p<0.001; Table 3) as well as in multivariate Cox-regressions analysis (p = 0.0030 before variable selection, Table 3, and p = 0.0026 after variable selection based on AIC, Table 4). Tumors with deletion 1p36 showed a recurrence rate of 25.9% (N = 14), tumors without this deletion showed a recurrence rate of 11.5% (N = 7).

Figure 4. Kaplan-Meier survival curves for time of recurrences of meningioma patients; patients are split into 2 subgroups according to Deletion of 1p36.

Table 4. Multivariate Cox-regression analysis with variable selection by AIC criterion.

Only 1.6% (1/62) of WHO I meningiomas and 5.7% (2/35) of WHO II meningiomas had a deletion of 9p21. On the other hand 50% (4/8) of anaplastic meningiomas showed this deletion (see also Table 3).

Hypermethylation of TIMP3 was found in 13.3% (14/105) of all cases. Breaking down the methylation results by the WHO grade, 6 cases (9.68%) belonged to WHO grade I, 7 cases (20%) to WHO grade II and 1 case (12.5%) to the anaplastic meningioma grade III (Table 1).There was an increasing rate of TIMP3 hypermethylation from grade I (9.68%) to grade II (20%). However due to the small number of cases of anaplastic meningiomas these results turned out to be not significant (p = 0.308; Table 1).

Comparison of TIMP3 hypermethylation between the time to recurrence of the given meningioma and the methylation status revealed in univariate Cox regression analysis no significant correlation (p = 0.799; Table 3). Interestingly the multivariate Cox regression analysis of the hypermethylation of the promoter TIMP3 and the time to recurrence turned out to be significant (p = 0.0475; Table 3).

The methylation of the tumor suppressor gene p16 was detected more frequently, but it was not associated with recurrence, higher grade, or chromosomal aberrations. Neither age nor sex had significant influence on tumor recurrence, with regard to the p16 methylation status.

In Table 5 the interaction of the investigated molecular markers which each other is shown. Only two marker pairs are significantly correlated: the deletion of chromosomal region 1p36 with the deletion of 22q (p = 0.0005), and the deletion of 1p36 with the deletion of 9p (p = 0.034). For all other markers no significant correlation could be observed. Since the deletions of 1p36 and 22q are highly correlated, but only deletion of 1p36 is associated with meningioma recurrence, we performed an analysis including only patients with deletion of 1p36. Comparing in this subgroup patients with and without deletion of 22q no significant difference between recurrence times was observed (p = 0.96, log rank test).


Grading of meningiomas has always been controversial. Obviously, the biological behaviour of meningiomas cannot be accounted by histological parameters alone [3], [4], [21], [31]. There is agreement in the literature that radical surgical extirpation is correlated with good prognosis [13], [14], [16], [22], [32], [52]. We therefore included only patients in our study whose tumor had been macroscopically completely removed, corresponding to Simpson grades I and II [43].

It is well known that females are affected far more frequently by meningiomas than males [9], [13], [21], [32], [38]. This observation was confirmed in our patients with a ratio of 2.6:1. This shift confirms earlier reports [3], [4], [5], [38], [46], [53].

In a panel of 105 meningiomas covering the different WHO grades, we assessed the methylation status of the tumor suppressor genes TIMP3 and p16 as related to their chromosomal aberrations (Table 1, 3).

The gene for the tissue inhibitor of metalloproteinase 3 (TIMP3) on 22q12.3 has been described as a tumorsupressor gene in different tumor entities [9], [13], [15].

In previous studies by Bello [54] and Lomas [55] hypermethylation of the TIMP3 gene resulting in silencing the tumorsupressor gene was more frequently detected in meningiomas with loss of 1p. Bello and coworkers found a correlations with loss of the genes THSB1 (47%), TIMP3 (24%), p73 (33%), p14ARF (23%) and p16 (23%). Also meningiomas with loss of 22q demonstrated a higher methylation status in this study [54]. Van Tilborg and co-workers reported hypermethylation of p16 in 62% of meningiomas with LOH of NF2 (located on 22q12.2) in contrast to the normal karyotype [56].

While Bello and colleagues [54] detected hypermethylation of TIMP3 5′-CpG island region in about 24% of meningiomas, Liu [57] could not validate these findings. Barski [9] assessed TIMP3 hypermethylation with MS-PCR and direct sodium bisulfite sequencing and revealed TIMP3 methylation in 67% of anaplastic meningiomas but less in atypical (22%) or benign meningiomas (17%).

In our present study we found that the rate of patients with TIMP3 methylation increases from 9.68% in grade I to 20% in grade II meningiomas. However, due to the low rate of the TIMP3 methylation in grade III meningiomas (1/8 caseş12.5%) in our study, overall TIMP3 methylation was not significantly correlated with tumor grade (p = 0.308, Fisher test).

Interestingly, the clinical follow-up data of the investigated meningioma patients revealed in the multivariate Cox-regressions analysis, that the methylation of the TIMP3 gene is significantly associated with a shorter time to recurrence (p = 0.0475; Table 3). These data require further investigations about the mechanism of inactivation of TIMP3 in meningiomas relating to a more aggressive clinical behaviour, which is discussed in the literature [9], [12], [14], [53].

Divergent results reported in the literature [9], [28], [54], [57] might stem from the different techniques and primer sites. Bello and Barski used different CpG islands as regions of interest for sequencing [9], [54]. As a result of these divergent findings with the failure of hypermethylation detection by Barski and colleagues at priming site -62 - 59 as well as the low hypermethylation rate in our sequencing analysis with primer site -50+2 we introduced the MS-PCR of a previously unaddressed, more distal region (-21 -18) for the methylation status analysis in our meningiomas [9], [54]. Therefore in our study the MS-PCR of the TIMP3 region was more sensitive and yielded more reliable results of methylation status. This is in line with previous reports. Generally, MS-PCR is known to be less prone to false positive results than sequencing [49]. Based on these finding all further analyses of methylation status were done by MS-PCR.

TIMP3 maps on 22q12, a chromosomal region that gets lost in about 50% of sporadic meningiomas [30]. This is consistent with previously reported data by Barski [9]. However, in our study TIMP3 methylation did not occur exclusively in meningiomas with deletions on 22q. This controversy is maybe caused by the retrospective panel of only 39 meningiomas investigated by Barski and colleagues.

Interestingly, loss of chromosome 1p - as an important genetic prognostic marker in meningiomas – and also loss of 9p – a typical chromosomal aberration in anaplastic meningiomas [2] – did not accompany hypermethylation of TIMP3.

The hypermethylation status of p16 did not coincide with chromosomal aberrations or high incidence of recurrences. LOH of 9p is very rare in meningiomas (6% of our patients) and was not concordant with the hypermethylation status of p16. Furthermore our results did not confirm the association of hypermethylation of p16 in meningiomas with LOH of the NF2 gene from the previous study by van Tilborg [56].

In Table 5 the dependence between the investigated molecular markers is analysed. Only two marker pairs are significantly correlated, deletion of chromosomal region 1p36 with deletion of 22q (p = 0.0005) and deletion of 1p36 with deletion of 9p (p = 0.034). For all other marker pairs no significant correlation could be found.

The significant association of the deletion of 22q with the deletion of one short arm of one chromosome 1 is in line with our previously published results describing the clonal cytogenetic evolution of meningiomas [3].

Although Barski et al. found in their study that in 20 of 39 investigated meningiomas the methylation of the TIMP3 status was associated with a micro deletion on the long arm of chromosome 22, we could not confirm these results. However, it must be given consideration that the monosomy 22 was ascertained by classic cytogenetic analyses in our study, whereas Barski and coworkers used microsatellite analyses using primers who span the TIMP3 region on chromosome 22 [3], [9].

After chromosome 22 anomalies, aberrations of the short arm of one chromosome 1 are the most frequent alterations detected by cytogenetic analysis of meningiomas [3], [4], [8], [21], [24], [28][33]. In a former study, we introduced the GPS established by cytogenetic analysis, as a marker for tumor progression. The GPS of a tumor is defined as the estimated average waiting time of its observed genetic pattern in a timed oncogenetic tree model. Using Cox regression analysis we demonstrated that for meningiomas the GPS has prognostic value with respect to clinical outcome and recurrence (p<0.001) [3].

In the present study we confirmed these previous results using the high resolution FISH-technology (iFISH) [3]. In univariate Cox regression analysis (p<0.001) as well as in multivariate Cox regression analysis (p = 0.0030 before variable selection and p = 0.0026 after variable selection based on AIC). deletion of 1p36 serves as an independent marker for the clinical behaviour of the given tumor.

In Figure 4 it is shown, that a deletion of 1p36, detected by iFISH in a given meningioma, can perfectly be used to identify a subgroup of tumors with poorer prognosis with respect to time to recurrence after surgery. Thus the genetic classification allows a prognostically significant distinction between low-risk and high-risk meningiomas at the time of primary surgery. It can be expected that a combination of both histopathological and cytogenetic descriptions of meningiomas could result in even improved prognostic accuracy [21], [23], [40], [42], [53].

Our results are in agreement with former cytogenetic investigations which indicated that the deletion of the distal part of the short arm of a chromosome 1 [1p-] is associated with progression in meningiomas [3], [4], [8], [21], [24], [28−33], [46], [58], . According to the above-mentioned findings, the deletion of chromosome 1p was ascertained to be an early and crucial event in the progression in meningiomas. By fitting multivariate Cox regression models we also found that for meningiomas the deletion of one short arm of one chromosome 1 has a very high impact concerning the biological behaviour in terms of recurrence and malignant behaviour (p = 0.00297,Table 3).

In conclusion, in this study we used iFISH that is easily applicable to clinical practice because it is not very time-consuming and can be applied to various clinical materials, including paraffin embedded tumor samples or dapped slides. Consequently, due to the common feasibility of the iFISH method a multimodal approach to meningioma grading, which is in our opinion the most promising for identifying meningiomas with an increased tendency to recur, is now available for almost all patients.

The TIMP3 inactivation by methylation seems to be also involved in meningioma progression, at least it is associated with a shorter time to recurrence using the multivariate Cox-regression analysis (p = 0.0475).

Based on the results of this study, the deletion of the short arm of one chromosome 1 is an independent prognostic factor which correlates significantly with increased risk of recurrence. After initial speculation on the role of 1p deletion for tumor recurrence [28] the importance of this aberration besides monosomy 22, 14 and 10 for the development of atypical and anaplastic meningiomas [18] and for progression from typical to atypical meningioma [3], [8] was pointed out.


We thank S. Wemmert and R. Koop for expert technical assistance and for helpful discussions.

Author Contributions

Conceived and designed the experiments: RK SU. Performed the experiments: SL DK CD RK. Analyzed the data: KK JR. Contributed reagents/materials/analysis tools: RK JO SU. Wrote the paper: RK JO JR SU. Operated the patients: RK JO. Conceived of the study: SU.


  1. 1. Beks JW, de Windt HL (1988) The recurrence of supratentorial meningiomas after surgery. Acta Neurochir (Wien) 95: 3–5.
  2. 2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215–225 discussion 226–219.
  3. 3. Ketter R, Urbschat S, Henn W, Feiden W, Beerenwinkel N, et al. (2007a) Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. Int J Cancer 121: 1473–1480.
  4. 4. Ketter R, Kim YJ, Storck S, Rahnenfuhrer J, Romeike BF, et al. (2007b) Hyperdiploidy defines a distinct cytogenetic entity of meningiomas. J Neurooncol 83: 213–221.
  5. 5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.
  6. 6. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, et al. (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146: 827–832.
  7. 7. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP (1993) Familial meningioma is not allelic to neurofibromatosis 2. Neurology 43: 2096–2098.
  8. 8. Zang KD (2001) Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 93: 207–220.
  9. 9. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20: 623–631.
  10. 10. Stuart MA, Lusis EA, Scheck AC, Coons MD, Lal AL, et al.. (2013) Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol, PMC2013 November 25.
  11. 11. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, et al. (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59: 798–802.
  12. 12. Bai YX, Yi JL, Li JF, Sui H (2007) Clinicopathologic significance of BAG1 and TIMP3 expression in colon carcinoma. World J Gastroenterol 13: 3883–3885.
  13. 13. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, et al. (2005) Frequent LOH on 22q12.3 and TIMP3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85: 165–175.
  14. 14. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, et al. (2008) Quantitative detection of TIMP3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep 20: 1489–1495.
  15. 15. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, et al. (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60: 1835–1839.
  16. 16. Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, et al. (2012) MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol 107: 617–631.
  17. 17. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, et al. (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159: 661–669.
  18. 18. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, et al. (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55: 149–158.
  19. 19. Ishino S, Hashimoto N, Fushiki S, Date K, Mori T, et al. (1998) Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer Jul 15 83(2): 360–6.
  20. 20. Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99: 379–391.
  21. 21. Muller P, Henn W, Niedermayer I, Ketter R, Feiden W, et al. (1999) Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res 5: 3569–3577.
  22. 22. Niedermayer I, Kolles H, Zang KD, Feiden W (1996) Characterization of intermediate type (WHO “atypical”) meningiomas. Clin Neuropathol 15: 330–336.
  23. 23. Sayagues JM, Tabernero MD, Maillo A, Diaz P, Rasillo A, et al. (2002) Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry 50: 153–159.
  24. 24. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, et al. (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55: 149–158.
  25. 25. Zang KD, Singer H (1967) Chromosomal consitution of meningiomas. Nature 216: 84–85.
  26. 26. Zang KD, Singer H (1968) The cytogenetics of human tumors. Angew Chem Int Ed Engl 7: 709–718.
  27. 27. Zang KD (1982) Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6: 249–274.
  28. 28. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, et al. (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9: 296–298.
  29. 29. Henn W, Cremerius U, Heide G, Lippitz B, Schroder JM, et al. (1995) Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas. Cancer Genet Cytogenet 79: 144–148.
  30. 30. Ketter R, Henn W, Niedermayer I, Steilen-Gimbel H, Konig J, et al. (2001) Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 95: 601–607.
  31. 31. Ketter R, Rahnenfuhrer J, Henn W, Kim YJ, Feiden W, et al. (2008) Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery 62: 61–69 discussion 69–70.
  32. 32. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, et al. (1997) Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 56: 879–886.
  33. 33. Urbschat S, Rahnenfuhrer J, Henn W, Feiden W, Wemmert S, et al. (2011) Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence. Int J Oncol 39: 1601–1608.
  34. 34. Deodhar K, Gheit T, Vaccarella S, Romao CC, Tenet V, et al. (2012) Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol 84: 1054–1060.
  35. 35. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789–799.
  36. 36. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686–692.
  37. 37. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, et al. (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129–133.
  38. 38. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, et al. (1995) Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531–4535.
  39. 39. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, et al. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837–841.
  40. 40. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.
  41. 41. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, et al. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756.
  42. 42. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115–177.
  43. 43. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20: 22–39.
  44. 44. Perry A, Stafford SL, Scheidhauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21: 1455–1465.
  45. 45. Perry A, Scheithauer BW, Stafford SL, Lohse CM Wollan PC (1999) “Malignancy” in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer 85: 2046–2056.
  46. 46. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of tumours of the central nervous system. WHO Classification of tumours of the central nervous system. IARC, Lyon.
  47. 47. Hopman AH, Ramaekers FC, Raap AK, Beck JL, Devilee P, et al. (1988) In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 89: 307–316.
  48. 48. Muellenbach R, Lagoda PJ, Welter C (1989) An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. Dec 5(12): 391.
  49. 49. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821–9826.
  50. 50. Righini CA, de Fraipont F, Reyt E, Favrot MC (2007) Aberrant methylation of tumor suppressor genes in head and neck squamous cell carcinoma: is it clinically relevant? Bull Cancer 94: 191–197.
  51. 51. Muhlisch J, Bajanowski T, Rickert CH, Roggendorf W, Wurthwein G, et al. (2007) Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 83: 17–29.
  52. 52. Al-Mefty O, Paulo A, Kadri S, Svetlana P, Jeffery RS, et al. (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101: 210–218.
  53. 53. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, et al. (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121: 714–723.
  54. 54. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, et al. (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108: 413–421.
  55. 55. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, et al. (2005) Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 42: 314–319.
  56. 56. van Tilborg AA, Morolli B, Giphart-Gassler M, de Vries A, van Geenen DA, et al. (2006) Lack of genetic and epigenetic changes in meningiomas without NF2 loss. J Pathol 208: 564–573.
  57. 57. Liu Y, Pang JC, Dong S, Mao B, Poon WS, et al. (2005) Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36: 416–425.
  58. 58. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW (1996) Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Cancer 77: 2567–2573.
  59. 59. Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neurooncol Nov 70(2): 183–202.